ANVS Company Profile and Key Details

Annovis Bio, Inc. (NYSE:ANVS) closed at $3.98 USD, gaining $0.33 (9.04%) from the previous close of $3.65. The stock is currently mid-range between its 52-week high and low $1.11 and $5.60. With a market capitalization of about $78.30 million, Annovis Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 1.89 million shares, volume is running light vs its 52-week average. Headquartered in Malvern, PA, Annovis Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maria L. Maccecchini, the company employs approximately 8 people and listed since January 29, 2020. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

Short-term trend indicators are bearishly aligned (SMA20 -14.14%, SMA50 20.37%, SMA200 52.32%). The stock’s 14-day RSI is 48.3 (neutral), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.82% below its high and over 228.83% above its low. Average 10-day trading volume of 728.59 thousand shares is below the 3-month average of 1.87 million, indicating normal recent market interest.

Annovis Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.86. This means the shares are trading above this model’s fair value.

Annovis Bio, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -73.95%. Wall Street analysts project EPS growth of 18.51% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.31. Next year's EPS is expected at $31.86. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $10.00. The high target offers 365.75% upside. The low target suggests 173.97% downside. The mean target is $13.50. This offers 269.86% upside. Annovis Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 2.78%. The prior quarter beat by -11.11%. Over the last six quarters, Apple has recorded several small beats. These include -37.14% in August 14, 2024.

Annovis Bio, Inc. has 26.50 million shares outstanding. The public float is 22.41 million shares, elevated short interest at 11.93% of float. This equals 2.83 million shares. The short ratio is 0.87 days. Institutional investors hold 17.14% of the float. Insiders own 14.86%. Hoffman Michael B holds 2.56 million shares, Maccecchini Maria-Luisa has 1.21 million shares and White Mark K. has 56.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Annovis Bio, Inc. trades at a P/E ratio of -2.35, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.01, also above market averages.

Our AI price prediction model suggests that Annovis Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 22.19%, with price expected at $4.46 by January 02, 2026, within a range of $3.76 to $5.23 3-Month Outlook: Projected fall of -64.11%, reaching $1.31 by March 19, 2026, with a range of $0.93 to $1.55. 1-Year Outlook: Projected gain of 374.25%, with price at $17.31 by December 18, 2026, within a range of $13.97 to $22.38.

Annovis Bio, Inc. (NYSE:ANVS) shares are down -27.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Annovis Bio, Inc. trading at a premium to the broader market with a P/E of -2.35. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.59, suggesting 957.26% upside. Our AI forecast model points to short-term strength (22.19% over two weeks), a medium-term fall (-64.11% over three months), and a longer-term gain (374.25% over one year), with expected trading ranges indicating moderate volatility.